Skip to main content

Table 4 Relationships between TME protein expressions and clinicopathologic parameters

From: PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas

 

PD-L1 in TCs

 

PD-L1 in TICs

 

PD-1+ TICs

 

VEGF in TCs

 

CD4+ TICs

 

CD8+ TICs

 

CD68+ TICs

 
 

High expression (n = 155)

Low expression (n = 66)

P-value

High expression (n = 36)

Low expression (n = 185)

P-value

High density (n = 131)

Low density (n = 90)

P-value

High expression (n = 151)

Low expression (n = 70)

P-value

High density (n = 117)

Low density (n = 104)

P-value

High density (n = 43)

Low density (n = 178)

P-value

High density (n = 129)

Low density (n = 92)

P-value

Age > 60

57 (37%)

23 (35%)

0.88

12 (33%)

68 (37%)

0.85

51 (39%)

29 (32%)

0.32

56 (37%)

24 (34%)

0.76

35 (30%)

45 (43%)

0.050

11 (26%)

69 (39%)

0.12

52 (40%)

28 (30%)

0.16

Endometrioid (vs. Non-endometrioid)

141 (91%)

55 (83%)

0.11

27 (75%)

169 (91%)

0.0089

110 (84%)

86 (96%)

0.0086

132 (87%)

64 (91%)

0.50

109 (93%)

87 (84%)

0.033

40 (93%)

156 (88%)

0.43

112 (87%)

84 (91%)

0.39

G1

95 (61%)

20 (30%)

3.2E-05

12 (33%)

103 (56%)

0.018

52 (40%)

63 (70%)

1.1E-05

76 (50%)

39 (56%)

0.47

65 (56%)

50 (48%)

0.28

25 (58%)

90 (51%)

0.40

65 (50%)

50 (54%)

0.59

G3

9 (6%)

16 (24%)

0.00026

7 (19%)

18 (10%)

0.14

17 (13%)

8 (9%)

0.39

21 (14%)

4 (6%)

0.11

12 (10%)

13 (13%)

0.67

7 (16%)

18 (10%)

0.28

17 (13%)

8 (9%)

0.39

MI > 1/2

47 (30%)

34 (52%)

0.0037

21 (58%)

60 (32%)

0.0044

50 (38%)

31 (34%)

0.67

67 (44%)

14 (20%)

0.00051

30 (26%)

51 (49%)

0.00044

13 (30%)

68 (38%)

0.38

53 (41%)

28 (30%)

0.12

LVI

52 (34%)

32 (48%)

0.049

24 (67%)

60 (32%)

0.00026

60 (46%)

24 (27%)

0.0047

64 (42%)

20 (29%)

0.054

46 (39%)

38 (37%)

0.68

18 (42%)

66 (37%)

0.60

55 (43%)

29 (32%)

0.12

FIGO stage I

104 (67%)

40 (61%)

0.36

19 (53%)

125 (68%)

0.125

81 (62%)

63 (70%)

0.25

88 (58%)

56 (80%)

0.0015

81 (69%)

63 (61%)

0.20

32 (74%)

112 (63%)

0.21

82 (64%)

62 (67%)

0.57

FIGO stage III-IV

37 (24%)

23 (35%)

0.10

16 (44%)

44 (24%)

0.014

42 (32%)

18 (20%)

0.064

48 (32%)

12 (17%)

0.024

30 (26%)

30 (29%)

0.65

10 (23%)

50 (28%)

0.57

40 (31%)

20 (22%)

0.17

MSI

29 (19%)

19 (29%)

0.11

12 (33%)

36 (19%)

0.078

38 (29%)

10 (11%)

0.0015

36 (24%)

12 (17%)

0.30

29 (25%)

19 (18%)

0.26

16 (37%)

32 (18%)

0.012

31 (24%)

17 (18%)

0.41

  1. Abbreviations: TME tumor microenvironment, PD-L1 programmed cell death-ligand 1, TCs tumor cells, TICs tumor-infiltrating immune cells, PD-1 programmed cell death-1, VEGF vascular endothelial growth factor, MI myometrial invasion, LVI lymphovascular space invasion, FIGO International Federation of Gynecology and Obstetrics, MSI microsatellite instability
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us